Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2004

01-07-2004

Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer

Authors: Volkmar Müller, Isabell Witzel, Hans Joachim Lück, Günter Köhler, Gunther von Minckwitz, Volker Möbus, Daniel Sattler, Waldemar Wilczak, Thomas Löning, Fritz Jänicke, Klaus Pantel, Christoph Thomssen

Published in: Breast Cancer Research and Treatment | Issue 1/2004

Login to get access
Metadata
Title
Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer
Authors
Volkmar Müller
Isabell Witzel
Hans Joachim Lück
Günter Köhler
Gunther von Minckwitz
Volker Möbus
Daniel Sattler
Waldemar Wilczak
Thomas Löning
Fritz Jänicke
Klaus Pantel
Christoph Thomssen
Publication date
01-07-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000032919.83803.48

Other articles of this Issue 1/2004

Breast Cancer Research and Treatment 1/2004 Go to the issue

OriginalPaper

Growth and EGFR Regulation in Breast Cancer Cells by Vitamin D and Retinoid Compounds

OriginalPaper

Estrogen Responsiveness of IBEP-2, A New Human Cell Line Derived from Breast Carcinoma

Erratum

Use of Complementary and Alternative Medicine by Chinese Women with Breast Cancer

OriginalPaper

Cytotoxic T Lymphocyte Antigen-4 Gene in Breast Cancer

OriginalPaper

Differential Gene Expression of TGFβ Inducible Early Gene (TIEG), Smad7, Smad2 and Bard1 in Normal and Malignant Breast Tissue

Instructions for Authors

Instructions for Authors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits